Flavia Jacobs, Medical Research Fellow at Institute Jules Bordet, recently shared on LinkedIn:
“Great to be at ESMO – European Society for Medical Oncology Breast Cancer again!
Happy to present my abstract: Adjuvant chemotherapy in stage I triple-negative breast cancer (TNBC): a systematic review and meta-analysis of survival outcomes
Honored that this work was also selected for a Merit Award.
Proud to see great work from my colleagues:
- First-line endocrine therapy plus CDK4/6 inhibitors in males with advanced HR+/HER2− breast cancer: real-world evidence from the PALMARES-2 study – led by Giuseppe Fotia
- A chemoresistance transcriptional signature identifies high-risk TNBC beyond pathologic complete response (pCR) – led by Giovanna Armani
Special thanks to our mentor and professor Claudio Vernieri Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
See you next year in Milan!”
Other Articles Featuring Flavia Jacobs On OncoDaily.
